McKinsey on Finance, Number 57

It might feel positively retro to apply discounted-cash-flow valuation to hot start-ups and the like. But it’s still the most reliable method.

Deal activity surged again this year—especially big deals and those in the United States.

The same handful of integration challenges vex companies year after year. New survey data suggest how high performers stay on top.

Under pressure to be active acquirers, some pharmaceutical and medical-products companies may be neglecting best practices. Here’s where they can most improve.